logo
Injectable asthma drug resolves dangerous food allergies in one-third of children

Injectable asthma drug resolves dangerous food allergies in one-third of children

Yahoo03-03-2025
More than a third of food-allergic kids were able to eat full servings of their trigger foods after treatment with an injectable asthma drug, new clinical trial findings report.
In all, 36% of children treated with omalizumab (Xolair) for a year successfully ate full servings of allergy-triggering foods, according to phase 2 trial results presented Sunday at a meeting of the American Academy of Allergy, Asthma & Immunology in San Diego.
By comparison, only 19% of children could do the same when given a shorter round of omalizumab followed by months of oral immunotherapy, a treatment through which patients build tolerance by eating gradually increasing amounts of food allergens.
Further, early stage 3 results from the clinical trial found that children retained some resistance to food allergies even after they stopped taking omalizumab, researchers reported.
"This is the first time we've been able to directly compare these two treatments for multiple food allergies, and our study shows omalizumab was superior to oral immunotherapy," principal investigator Dr. Robert Wood, director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children's Center, said in a news release.
Food allergies are common, affecting 8% of U.S. children and 10% of adults, researchers said in background notes.
Omalizumab works by binding to the antibodies that promote allergic reactions, rendering them inactive, researchers said in background notes.
The drug has been on the market since 2003, first approved by the U.S. Food and Drug Administration as a preventive treatment for allergic asthma, according to Drugs.com.
And based on early results from this clinical trial, the FDA approved omalizumab as a treatment for food allergies in adults and children as young as 1 year old, researchers said in background notes.
The stage 2 clinical trial involved 117 children with an average age of 7 who were allergic to peanuts and at least two other common food allergens -- milk, egg, cashew, wheat, walnut or hazelnut.
At week 44, the children were fed all three of their food allergens in amounts equivalent to about 20 peanuts or a half-cup of milk.
The lower results for children on oral immunotherapy were driven by the fact that more of these kids had to drop out of the study due to adverse reactions, researchers said.
About 88% of children treated with omalizumab finished the stage 2 trial, compared with 51% of those receiving oral immunotherapy, results show.
No children taking omalizumab experienced serious adverse reactions, compared with more than 30% of those treated with oral immunotherapy.
"We have demonstrated that there are multiple paths to living a safe life with food allergies," senior researcher Dr. Sharon Chinthrajah, acting director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford Medicine, said in a news release.
"This study is very encouraging because it shows that we have treatment choices for our patients that are safe and not too burdensome," she added.
Researchers at the AAAAI meeting also presented preliminary results from stage 3 of the clinical trial, which focused on the first 60 children in the study.
Stage 3 focused on different pathways that children with food allergies might take in real-world settings, after they've gained tolerance to trigger foods through omalizumab therapy.
Each of the children was assigned one of three strategies for each of their food allergens -- start eating the food, continue with oral immunotherapy or avoid the food.
These strategies were assigned based on how the kids responded to a food challenge following omalizumab treatment.
More than 80% of the plans began with the kids eating the foods to which they'd been allergic, results show.
The kids were then tracked for a year to see how they fared.
Preliminary results show that consumption of milk, egg and wheat had a greater success rate (61% to 70%) than peanuts and tree nuts (38% to 56%).
In most cases, kids ate declining amounts of their allergens during the follow-up period. Some adverse events occurred, including food reactions severe enough to require an epinephrine shot.
Stage 3 is ongoing, with completion expected this summer, researchers said.
"While the results of Stage 3 are still preliminary, the majority of the first 60 participants were able to successfully introduce allergenic foods into their diet after stopping omalizumab," lead researcher Dr. Jennifer Dantzer, a pediatric allergist at Johns Hopkins Children's Center, said in a news release.
"Omalizumab is currently approved in the U.S. for the reduction of allergic reactions that may occur with accidental exposures," Dantzer said. "These results indicate that omalizumab may have additional uses that may be valuable for patients, but the potential risks should be recognized."
Funding for the clinical trial came from Genentech and Novartis, the makers of omalizumab.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The American Academy of Allergy, Asthma & Immunology has more about food allergies.
Copyright © 2025 HealthDay. All rights reserved.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fast Five Quiz: Asthma Control and Long-term Outcomes
Fast Five Quiz: Asthma Control and Long-term Outcomes

Medscape

time42 minutes ago

  • Medscape

Fast Five Quiz: Asthma Control and Long-term Outcomes

Learn more about asthma control guidance. The GINA report notes that a history of one or more asthma exacerbations within the previous year is a well-established risk factor for future exacerbations, regardless of current symptom control. According to the same report, additional risk factors that similarly raise the risk for asthma flare-ups, regardless of how well symptoms are managed, include low socioeconomic status, poor adherence to medication, incorrect inhaler technique, reduced forced expiratory volume in one second, active smoking habit, and increased blood eosinophil counts. Thrombocytopenia, low oxygen saturation at rest, and alcohol use disorder are not among the risk factors for asthma exacerbations that are independent of symptom control. Learn more about working with patients to set and achieve long-term goals of asthma management. The latest GINA report encourages healthcare providers to assess asthma symptom control at every opportunity, including during routine prescribing and dispensing. The report emphasizes the importance of directed questioning, given symptom frequency and severity and treatment goals can significantly differ between patients and other current recommendations. Frequency of asthma symptoms, night waking, and short-acting beta-agonist use for symptom relief are some suggested question topics included in the GINA report. Learn more about asthma workup. The GINA report lists three integral facets of impactful asthma self-management instruction: a written action plan delineating recognition and response to worsening asthma, symptom and/or PEF self-monitoring, and regular review by a healthcare provider. Self-management that includes a written action plan is associated with reduced emergency department visits and hospitalizations. Although patients might find PEF monitoring helpful in certain circumstances, such as after an exacerbation or change in treatment, no specific frequency is endorsed. Self-adjustment of medications is not a required part of guided asthma self-management. No significant difference in self-management effectiveness has been identified whether the patient self-adjusts medication or if changes are made by a healthcare provider. While regular review by a clinician is an essential factor in asthma self-management education, the exact interval of these reviews is not specified. Learn more about control-based asthma management. In the latest GINA report, patients' establishing goals for their asthma and treatments is a part of disease assessment and control during management. This can help patients achieve optimal long-term asthma outcomes. Physician changes, medication dependency, and activity level modifications can be part of long-term control of asthma, but they greatly depend and vary based on the patient, their goals, and their treatment plan and are not always recommended. Learn more about long-term goals of asthma management. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: Science Source

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Yahoo

timea day ago

  • Yahoo

Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR

Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032. San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 163,149.35 million by 2032. This extraordinary growth is propelled by the increasing adoption of bispecific antibody therapies in oncology and immunology, groundbreaking clinical outcomes, and robust R&D investments aimed at next-generation biologics. Bispecific antibodies are bioengineered molecules designed to simultaneously recognize and bind to two different antigens or epitopes. Unlike monoclonal antibodies that target a single antigen, bispecific antibodies can link a disease-related antigen (such as one found on cancer cells) to another molecule—often a T-cell—thus redirecting immune cells to attack malignant tissues with heightened precision. This dual-binding capability is unlocking new therapeutic possibilities in cancer, autoimmune diseases, and infectious diseases. As of 2024, over 300 bispecific antibodies are in global clinical development, with 14 already approved by the U.S. FDA, reflecting the sector's rapid growth and clinical validation. Download Free Sample Report PDF @ Global Bispecific Antibodies Market Key Players- Detailed Competitive Insights Amgen Genentech Akeso, Inc. Taisho Pharmaceutical Janssen Immunocore Adimab, Innovent Biologics, Inc. AstraZeneca Affimed GmbH Xencor F. Hoffmann-La Roche Ltd. Sanofi Regeneron Pharmaceuticals Inc. Pieris Pharmaceuticals, Inc. Eli Lilly Mereo BioPharma Group plc Merus MacroGenics, Inc. Sobi, TG Therapeutics Inc. Genmab A/S Alteogen Emergent BioSolutions Inc. Novartis AG Astellas Pharma Inc. Celgene Corporation Others Market Drivers 1. Increasing Cancer Prevalence Globally Cancer remains a global health crisis, with the World Health Organization (WHO) estimating around 19.3 million new cancer cases and nearly 10 million deaths in 2023 alone. Traditional therapies are often limited by poor specificity and severe side effects, which have shifted the focus toward more targeted modalities, such as bispecific antibodies. Their unique mechanism allows precise tumor targeting while preserving healthy tissues, making them a preferred choice for next-gen cancer therapies. 2. Regulatory Approvals and Accelerated Development Pathways The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have actively supported innovative antibody therapeutics. Between 2022 and 2024, the FDA approved six bispecific antibodies, a testament to their growing clinical value. Regulatory agencies are also introducing expedited pathways for breakthrough therapies, speeding up market entry for promising candidates. 3. Rising Investments in Immunotherapy and Biologics Governments and private players are significantly boosting funding for immunotherapy research. For instance, the U.S. National Cancer Institute (NCI) allocated over USD 15 billion toward cancer research in 2023, a portion of which is directed toward the development of targeted therapies, including bispecific antibodies. This capital influx is catalyzing clinical trials, molecule discovery, and scalable manufacturing solutions. Market Challenges Despite the optimistic trajectory, the bispecific antibodies market faces notable challenges: Complex Manufacturing: Producing bispecific antibodies involves intricate processes, such as protein folding and stability optimization, which increase production time and cost. High Development Costs: The R&D cycle for bispecific therapies is long and resource-intensive, often requiring large-scale trials and advanced biotechnological platforms. Immunogenicity Risks: Some bispecific formats can trigger unwanted immune responses, complicating their clinical profiles. Nonetheless, advances in antibody engineering, such as the development of Fc-engineered antibodies and T-cell engaging bispecifics (BiTEs), are helping overcome these limitations. Regional Insights North America is poised to maintain a dominant position in the global bispecific antibodies market. Its leadership is driven by: A well-established biotech and pharma industry. Substantial government and private R&D investments. Early and streamlined regulatory approvals. In 2023 alone, the U.S. government dedicated nearly USD 7.9 billion toward cancer research, a portion of which supports novel antibody-based treatments. Moreover, the presence of major biopharmaceutical companies and academic research centers ensures rapid clinical development. Asia-Pacific, on the other hand, is anticipated to experience the fastest growth rate. Countries such as China, India, and South Korea are: Increasing healthcare expenditures. Encouraging local biotech innovation. Expanding access to clinical trials and biologic therapies. China, for example, is investing heavily in biologics manufacturing capabilities and has introduced supportive regulations for fast-track drug approval, which will likely make the region a future hub for bispecific antibody development. TABLE OF CONTENT 1. Bispecific Antibodies Market Overview 1.1. Study Scope 1.2. Market Estimation Years 2. Executive Summary 2.1. Market Snippet 2.1.1. Bispecific Antibodies Market Snippet by Drug Type 2.1.2. Bispecific Antibodies Market Snippet by Indication 2.1.3. Bispecific Antibodies Market Snippet by Distribution Channel 2.1.4. Bispecific Antibodies Market Snippet by Country 2.1.5. Bispecific Antibodies Market Snippet by Region 2.2. Competitive Insights 3. Bispecific Antibodies Key Market Trends 3.1. Bispecific Antibodies Market Drivers 3.1.1. Impact Analysis of Market Drivers 3.2. Bispecific Antibodies Market Restraints 3.2.1. Impact Analysis of Market Restraints 3.3. Bispecific Antibodies Market Opportunities 3.4. Bispecific Antibodies Market Future Trends…… Get a detailed analysis on regions, market segments, customer landscape, and companies@ Market Segmentation by Indication The bispecific antibodies market is segmented by application into: Cancer Autoimmune and Inflammatory Disorders Others Among these, the oncology segment is forecasted to command the largest share throughout the forecast period. As of March 2025, over 650 bispecific antibodies are in clinical development globally—nearly all focused on oncology applications, and nine of the 11 bispecifics approved since 2021 target cancer, representing over 80% of recent regulatory approvals. Competitive Landscape & Innovation Strategies The bispecific antibody space is rapidly evolving with heightened competition among biotech giants and emerging players. Leading companies are prioritizing: Next-generation platforms for greater safety, flexibility, and efficacy. Strategic collaborations and licensing deals to expand pipeline access. Geographic expansion into emerging economies with rising healthcare demands. Biotech firms are utilizing AI-driven drug discovery, cell-line optimization, and novel bispecific formats (like dual-variable domain antibodies and knob-into-hole technologies) to advance their products. Some players are also entering into co-development agreements to reduce costs and accelerate regulatory milestones. Future Outlook The bispecific antibodies market is positioned at the forefront of immunotherapeutic innovation. With strong clinical potential, increasing funding, and a favorable regulatory climate, the sector is expected to witness substantial growth through 2032. As manufacturing bottlenecks are resolved and newer formats with improved safety emerge, bispecific antibodies will likely become standard components of combination therapies in oncology and immune-related disorders. In conclusion, the bispecific antibodies market offers immense opportunities for stakeholders across biotechnology, healthcare, and investment sectors. Its rapid evolution signals a paradigm shift in how complex diseases are treated, ushering in a new era of precision medicine. Browse more Reports from AnalystView Market Insights:CONTACT: U.S. Office: 11923 NE Sumner St STE 750924 Portland, Oregon, 97220, USA Phone: +1 615-326-5253 (U.S. Toll Free) Email: mayank@ Email: inquiry@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth
Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth

Yahoo

time2 days ago

  • Yahoo

Kisqali Emerges as Novartis AG (NVS) Blockbuster with Record Q2 Growth

We recently published Novartis AG stands third among the most undervalued stocks. Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on developing innovative treatments across oncology, immunology, neuroscience, cardiovascular, and renal diseases. The company continues to invest heavily in research and development, aiming to deliver breakthrough medicines that improve patient outcomes worldwide. The company's Kisqali (ribociclib) has emerged as a major growth driver, with Q2 2025 sales surging 64% globally and 100% in the U.S. It targets metastatic breast cancer and is positioned as a potential blockbuster. Other notable therapies include Pluvicto for prostate cancer and Scemblix for chronic myeloid leukemia, both showing strong commercial momentum. Novartis AG (NYSE:NVS) is expanding its presence in nephrology. Vanrafia (atrasentan) recently received FDA accelerated approval for reducing proteinuria in IgA nephropathy, marking a key advancement. Fabhalta (iptacopan), an oral treatment for C3 glomerulopathy, also gained approval. Ongoing trials include zigakibart, a Phase III candidate for IgAN, with results expected in 2026. The business introduced Coartem Baby, a pediatric malaria treatment approved by Swissmedic. It addresses the unmet need for infants under 5 kg with a cherry-flavored, easily dissolvable formulation. Novartis AG (NYSE:NVS) plans to launch it on a not-for-profit basis in malaria-endemic regions. A pharmacy technician in a laboratory preparing medication for retail distribution. The corporation has streamlined its pipeline around core therapeutic areas, with several Phase III trials in progress. These include remibrutinib for autoimmune diseases, ianalumab for lupus, and YTB323 for neuroimmunological disorders. The company expects 15 submission-enabling data readouts over the next two years, which underscores a robust late-stage pipeline. While we acknowledge the potential of NVS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store